文献速递肺血管病与心包/心肌炎

SIN3a通过调控BMPR2甲基化与表达作为肺动脉高压治疗新机制

Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension.
PubMed 文献 · Circulation · 2021-06-03

该研究探讨了转录调节因子SIN3a在肺动脉高压(PAH)表观遗传机制中的作用。研究使用PAH患者肺样本、临床前小鼠和大鼠PAH模型及人肺动脉平滑肌细胞,发现SIN3a通过抑制BMPR2启动子甲基化上调BMPR2表达,并鉴定肺靶向AAV1-SIN3a基因治疗在啮齿类PAH模型中具有治疗益处。

要点

  • SIN3a在PAH患者和啮齿类模型中表达失调,与BMPR2表达降低强相关。
  • SIN3a过表达通过阻止BMPR2启动子甲基化上调BMPR2并抑制人肺动脉平滑肌细胞增殖。
  • 气管内递送AAV1-SIN3a可减轻PAH啮齿类模型的肺血管和右心室重构。

核心结论

  • SIN3a在肺动脉高压中具有保护性有益作用。
  • SIN3a在人肺动脉平滑肌细胞中通过新机制调控BMPR2。
  • 肺靶向AAV1-SIN3a基因治疗是治疗PAH的新兴有前景策略。

研究设计与样本

  • 使用PAH患者和非PAH对照的肺样本、临床前小鼠和大鼠PAH模型及人肺动脉平滑肌细胞。
  • 体外通过慢病毒载体或siRNA调控SIN3a表达,体内通过特定AAV1或慢病毒编码人SIN3a调控。

主要发现

  • 在患者和啮齿类模型中检测到SIN3表达失调,与BMPR2表达降低强相关。
  • SIN3a过表达抑制人肺动脉平滑肌细胞增殖,并通过阻止BMPR2启动子区域甲基化上调BMPR2表达。
  • RNA测序提示SIN3a下调DNMT1和EZH2表达,同时促进TET1表达。
  • SIN3a通过减少CTCF与BMPR2启动子结合促进BMPR2表达。
  • 气管内递送AAV1人SIN3a减轻肺血管和右心室重构、降低右心室收缩压和平均肺动脉压、恢复BMPR2表达。

临床怎么用

  • 肺靶向AAV1-SIN3a基因治疗可能成为治疗PAH患者的新策略。
  • SIN3a-BMPR2轴及DNMT1、EZH2、TET1、CTCF等分子可作为PAH表观遗传干预的潜在靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epigenetic mechanisms are critical in the pathogenesis of pulmonary arterial hypertension (PAH). Previous studies have suggested that hypermethylation of the BMPR2 (bone morphogenetic protein receptor type 2) promoter is associated with BMPR2 downregulation and progression of PAH. Here, we investigated for the first time the role of SIN3a (switch-independent 3a), a transcriptional regulator, in the epigenetic mechanisms underlying hypermethylation of BMPR2 in the pathogenesis of PAH. METHODS: We used lung samples from PAH patients and non-PAH controls, preclinical mouse and rat PAH models, and human pulmonary arterial smooth muscle cells. Expression of SIN3a was modulated using a lentiviral vector or a siRNA in vitro and a specific adeno-associated virus serotype 1 or a lentivirus encoding for human SIN3a in vivo. RESULTS: SIN3a is a known transcriptional regulator; however, its role in cardiovascular diseases, especially PAH, is unknown. It is interesting that we detected a dysregulation of SIN3 expression in patients and in rodent models, which is strongly associated with decreased BMPR2 expression. SIN3a is known to regulate epigenetic changes. Therefore, we tested its role in the regulation of BMPR2 and found that BMPR2 is regulated by SIN3a. It is interesting that SIN3a overexpression inhibited human pulmonary arterial smooth muscle cells proliferation and upregulated BMPR2 expression by preventing the methylation of the BMPR2 promoter region. RNA-sequencing analysis suggested that SIN3a downregulated the expression of DNA and histone methyltransferases such as DNMT1 (DNA methyltransferase 1) and EZH2 (enhancer of zeste 2 polycomb repressive complex 2) while promoting the expression of the DNA demethylase TET1 (ten-eleven translocation methylcytosine dioxygenase 1). Mechanistically, SIN3a promoted BMPR2 expression by decreasing CTCF (CCCTC-binding factor) binding to the BMPR2 promoter. Last, we identified intratracheal delivery of adeno-associated virus serotype human SIN3a to be a beneficial therapeutic approach in PAH by attenuating pulmonary vascular and right ventricle remodeling, decreasing right ventricle systolic pressure and mean pulmonary arterial pressure, and restoring BMPR2 expression in rodent models of PAH. CONCLUSIONS: All together, our study unveiled the protective and beneficial role of SIN3a in pulmonary hypertension. We also identified a novel and distinct molecular mechanism by which SIN3a regulates BMPR2 in human pulmonary arterial smooth muscle cells. Our study also identified lung-targeted SIN3a gene therapy using adeno-associated virus serotype 1 as a new promising therapeutic strategy for treating patients with PAH.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Bisserier M, Mathiyalagan P, Zhang S, et al. Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension. Circulation. 2021. PMID: 34078089. doi:10.1161/CIRCULATIONAHA.120.047978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。